Acute pseudogout after cinacalcet treatment

The EVOLVE trial showed that up to 58.3% of patients treated with cinacalcet developed hypocalcemia, albeit mostly asymptomatic and of minor clinical relevance.1 We treated an 80-year-old woman who had hypercalcemic primary hyperparathyroidism with cinacalcet, 30 mg/d. At baseline, her total serum calcium was 2.84 mmol/l. After 14 days of cinacalcet, she developed polyarthralgia and myalgia but no fever. Laboratory studies showed serum calcium of 2.05 mmol/l and C-reactive protein of 138 mg/l, but there was no leukocytosis.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Letter to the Editor Source Type: research